Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies

BACKGROUND: When epidermal growth factor receptor (EGFR) gene mutation-positive non-small cell lung cancer (NSCLC) acquires resistance to the initial tyrosine kinase inhibitor (TKI) treatment, reassessing the tumor DNA by re-biopsy is essential for further treatment selection. However, the process o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pulm Med
Main Authors: Uozu, Sakurako, Imaizumi, Kazuyoshi, Yamaguchi, Teppei, Goto, Yasuhiro, Kawada, Kenji, Minezawa, Tomoyuki, Okamura, Takuya, Akao, Ken, Hayashi, Masamichi, Isogai, Sumito, Okazawa, Mitsushi, Hashimoto, Naozumi, Hasegawa, Yoshinori
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5719748/
https://ncbi.nlm.nih.gov/pubmed/29212495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-017-0514-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados